EIF’s National Women’s Cancer Research Alliance is one of three major initiatives within EIF’s Women’s Cancer Programs. Through EIF's National Women's Cancer Research Alliance, co-founded with cancer activist Lilly Tartikoff, EIF funds some of the most promising research being conducted today to develop new and more effective approaches to the treatment of women's cancers. EIF grants have helped accelerate research that contributed to the development of a breakthrough gene treatment called Herceptin®, the first successful drug that seeks out a particular gene found in one of three cases of the most aggressive form of breast cancer.

After extensive trials, Dr. Dennis Slamon, director of the Revlon / UCLA Women's Cancer Research Program and chair of EIF's NWCRA Medical Advisory Board, announced that Herceptin® received FDA approval years ahead of schedule - ultimately saving the lives of countless women around the world. EIF grants have also supported other state-of-the-art therapies bringing new and innovative treatment approaches to breast cancer worldwide.

Click here to learn more about the individual grantees.